Biotech · Public company · Cambridge, MA, US
Fulcrum Therapeutics, Inc.
Ticker FULC · SEC CIK 0001680581
Track this companyFree. Adds Fulcrum Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials90 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline10
- LosmapimodPhase 3 · Facioscapulohumeral Muscular Dystrophy (FSHD)ClinicalTrials.gov · fetched Nov 12, 2026
- Losmapimod oral tabletPhase 3 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- Losmapimod oral tabletPhase 2 · Facioscapulohumeral Muscular Dystrophy (FSHD)ClinicalTrials.gov · fetched Nov 12, 2026
- PociredirPhase 2 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- FTX-6058 - Two Dosing PeriodsPhase 1 · Healthy Adult SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- FTX-6058 / Midazolam SyrupPhase 1 · Healthy Adult SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Losmapimod 15 mg oral tabletPhase 1 · Healthy Adult SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Losmapimod one 15 mg oral tabletPhase 1 · Healthy Adult SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Losmapimod two 7.5 mg oral tabletsPhase 1 · Healthy Adult SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Pociredir oral capsule(s)Phase 1 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Open-Label Extension Study to Pioneer Study 6058-SCD-101PHASE2 · TERMINATED · started Mar 30, 2026ClinicalTrials.gov NCT07401823 · fetched Nov 12, 2026
- Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell DiseasePHASE1 · TERMINATED · started Dec 13, 2025ClinicalTrials.gov NCT07431398 · fetched Nov 12, 2026
- Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)PHASE3 · TERMINATED · started Jun 16, 2022ClinicalTrials.gov NCT05397470 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PociredirPHASE1 · COMPLETED · started Dec 13, 2021ClinicalTrials.gov NCT05169580 · fetched Nov 12, 2026
- Relative Bioavailability and Food Effect Study of Losmapimod 15 mg TabletsPHASE1 · COMPLETED · started Aug 19, 2021ClinicalTrials.gov NCT05002231 · fetched Nov 12, 2026
- Safety, Tolerability and Pharmacokinetics of FTX-6058PHASE1 · COMPLETED · started Oct 26, 2020ClinicalTrials.gov NCT04586985 · fetched Nov 12, 2026
- Losmapimod Safety and Efficacy in COVID-19PHASE3 · TERMINATED · started Aug 28, 2020ClinicalTrials.gov NCT04511819 · fetched Nov 12, 2026
- Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)PHASE2 · TERMINATED · started Feb 13, 2020ClinicalTrials.gov NCT04264442 · fetched Nov 12, 2026
- Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)PHASE2 · COMPLETED · started Aug 9, 2019ClinicalTrials.gov NCT04003974 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Aug 17, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 1, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Apr 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 27, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 24, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 24, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 12, 2026 · fetched Nov 12, 2026